In Brief: FemRx
This article was originally published in The Gray Sheet
Executive Summary
FemRx: Plans on launching its Diva laparoscopic morcellator for use with the firm's OPERA (Out-Patient Endometrial Resection/Ablation) system during the third quarter, Andrew Thompson, president and chief executive officer of FemRx said at the June 19 Dillon, Read & Co. Medical Technology meeting in New York City. During the fourth quarter FemRx plans on launching its Pearl technology, which allows OPERA equipment to be used with normal saline. In 1998 the company plans on introducing the StarLight, which will be "the smallest continuous flow resectoscope on the market," Thompson said. FemRx also is developing the Soprano cryothermic global ablation system, which the company hopes to introduce in 1999...